This page lists past opportunities from CIP.
Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.
David Beylin, M.S., NCI, Phone: 301-496-0079, Email: firstname.lastname@example.org
Expires January 8, 2013
These Funding Opportunity Announcements (FOA) support the development and clinical validation of systems for image-guided interventions (IGIs) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; the validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multisite clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals..
Contact: Keyvan Farahani, Ph.D. (email@example.com) at 240-276-5921
The NCI encourages innovative translational research in the development of quantitative in vivo imaging characterization of image-guided drug delivery (IGDD) in cancer, including characterizations of the target, delivery validation, and therapy response. This initiative will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer. Validation studies in non-human primates or large animal models and first in human studies directed towards translation of IGDD technology into the clinic will be considered appropriate for this initiative.
See full description in NIH Guide: PA-09-253
Anne Menkens, Ph.D. (firstname.lastname@example.org) at 301-496-9531
The Cancer Imaging Program, and the Division of Cancer Diagnosis and Treatment, at the National Cancer Institute (NCI), invite new or renewal (competing) applications for P50 Research Center Grants for In vivo Cellular and Molecular Imaging Centers (ICMICs). The program will fund the 5-year P50 ICMIC grants to support interdisciplinary scientific teams conducting cutting-edge cancer molecular imaging research. ICMIC funding is designed to: (1) support innovative cancer molecular imaging research projects; (2) support unique core facilities; (3) enable the awardees to initiate pilot research in new promising directions; and (4) provide interdisciplinary career development opportunities for investigators new to the field of molecular cancer imaging.
See full description in NIH Guide:PAR-09-157
Robert J. Nordstrom, Ph.D. (email@example.com) at 301-594-9121
The Cancer Imaging Program, (NCI), solicits applications to promote research on quantitative imaging of tumor response to cancer therapies in clinical trial settings, with the overall goal of facilitating clinical decision making. Proposed projects should include the appropriate development and adaptation/implementation of quantitative imaging methods, protocols and software solutions/tools (using existing commercial imaging platforms and instrumentation), and their application in current and planned Phase 1-2 clinical therapy trials. No support for the clinical trials, as such, will be provided under this initiative. The proposed projects must focus on imaging-derived quantitative measurements of responses to drugs and/or radiation therapy, and/or image-guided interventions. It is anticipated that these research goals will require multidisciplinary efforts. Therefore, this announcement solicits applications from multi-disciplinary teams to include oncologists as well as clinical and basic imaging scientists. The involvement of industrial partners in the development of the quantitative imaging methods is not required, but is strongly encouraged. Awardees will form a Quantitative Imaging Network (QIN) to share ideas and approaches to validate and standardize imaging data and related imaging meta-data for quantitative measurements of responses to cancer therapies.
See full description in NIH Guide: PAR-08-225
Barbara Galen, M.S.N., C.R.N.P., C.N.M.T., NCI, Phone: 301-594-5225, Email: firstname.lastname@example.org
Lalitha Shankar, M.D., NCI, Phone: 301-496-9531, Email: email@example.com
Keyvan Farahani, Ph.D., NCI, Phone: 301-451-2651, Email: firstname.lastname@example.org
The goal of this Funding Opportunity Announcement (FOA) is to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, and 3-D reconstruction and other quantitative tools. The rapid translation of promising discoveries in the fields of imaging probes, methodologies, technologies and image-guided therapies to clinical practice requires timely support. This FOA will provide investigators with support for either pilot (Phase I and II) cancer clinical trials, or patient monitoring and laboratory studies. The imaging and Image-guided Intervention (IGI) studies, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or Cooperative Groups.
Mechanism of support: This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism
See full description in NIH Guide:PAR-08-147
For instructions on the inclusion of clinical protocols in the PAR-08-147 application, see NOT-CA-10-019
Heng Xie, Ph.D.,, NCI, Phone: 301-496-8866, Email: email@example.com
This Funding Opportunity Announcement (FOA) is intended to promote translational research in new agent/modality development with timely exploitation of new cancer-relevant therapeutic and/or preventive strategies that involve defined molecular targets. Applications are solicited for pilot clinical trials exploring individual anticancer agents/modalities and/or their combinations in the context of specific molecular targets. Applicants may propose Phase 0, Phase I, Phase II, and/or other pilot cancer clinical trials. In addition, patient monitoring and laboratory correlative studies related to clinical trials may be proposed. Applications that explore complementary and alternative approaches for cancer prevention and/or treatment are also encouraged. Clinical trials proposed may be oriented on AIDS-associated malignancies and cancer-related nutritional interventions. Applicants must include the clinical protocol within the Appendix to ensure proper accelerated peer review with the goal of issuing new awards within 6 months of receipt of the grant application.
Mechanism of Support: This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism
See full description in NIH Guide:PAR-08-025
Houston Baker, Ph.D., Phone: 310-594-9117; E-mail: firstname.lastname@example.org
Laurence Clarke, Ph.D., Phone: 301-435-9190; E-mail: email@example.com
Robert Nordstrom, Ph.D., Phone: 301-594-9192; E-mail: firstname.lastname@example.org
Keyvan Farahani, Ph.D., Phone: 301-451-2651; E-mail: Farahani@mail.nih.gov
Guoying Liu, Ph.D., Phone: 301-594-5220; E-mail: email@example.com
Guilllermo Marquez, Ph.D., Phone 310-451-3896; E-mail: firstname.lastname@example.org
This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI) is an open competition initiative, designed to continue the efforts of the NCI to develop and translate cancer-relevant optical imaging technologies as a part of an overall imaging program for early cancer detection, diagnosis, therapeutic response, drug development, and image-guided therapy. This FOA stems from the previous initiative on optical imaging technology. However, the program structure and goals of the current FOA differ from those of the original program. Accordingly, all responses to this FOA will be considered new applications, with the main objective being to accelerate the translational research of in vivo multimodal imaging and/or spectroscopic platforms from the laboratory and pre-clinical level to the clinical level. Applications are sought from multi-disciplinary, multi-institutional research teams. After the awards, successful teams will become Centers that will be organized into an interactive network. The network will be called the "Network for Translational Research: Optical Imaging" (NTR). The purpose of NTR is to develop, optimize, and validate imaging technology platforms and methods so that they can enter single or multi-site clinical trials and eventually be incorporated into clinical practice. Applicants responding to this FOA must identify a specific cancer-relevant clinical goal and propose to develop and validate at least one multimodal imaging platform, as defined in this FOA, to address this clinical goal.
See full description in NIH Guide: RFA-CA-08-002
Keyvan Farahani, Ph.D. (email@example.com) at 301-451-2651
The National Cancer Institute (NCI) is seeking research project (R01) applications to conduct translational, clinical, therapeutic, and preventive studies and trials of neoplastic diseases in humans and encourages clinical researchers to collaborate with basic scientists to translate insights in cancer genetics, cancer epigenetics, and cancer biology, coupled with the development of new anti-cancer agents, into innovative cancer intervention studies and trials. The overall aims of this funding opportunity announcement (FOA) are two-fold: (1) to stimulate the development of innovative cancer prevention and therapy clinical trials with or without laboratory correlative studies; and (2) to support innovative correlative laboratory studies retrospectively and prospectively linked to therapeutic/preventive clinical trials. Investigators may address either aim in their applications.
See full description in NIH Guide: PA-07-356
These Funding Opportunity Announcements (FOA) support the development and clinical validation of systems for image-guided interventions (IGIs) for cancer. Specifically, the goals of this program are to provide support for: the development and optimization of fully integrated cancer imaging, monitoring, and therapy systems; the validation of integrated IGI systems through clinical evaluations; the development of multiple prototype integrated IGI systems as required for multisite clinical evaluations; and partnerships among small business, large business, and academic clinical centers, as well as small business joint ventures, in order to reach the research goals.
This Funding Opportunity Announcement (FOA) issued by the Cancer Imaging and Radiation Research Programs of the National Cancer Institute (NCI), National Institutes of Health (NIH), encourages applications from research partnerships formed by academic and industrial investigators to accelerate the translation of either animal or human in vivo imaging, image guided, and/or spectroscopic systems and methods designed to solve targeted cancer problems for cancer research, clinical trials, and/or clinical practice. The partners on each application will establish an inter-disciplinary, multi-institutional research team to work in a strategic alliance to implement a coherent strategy to develop and translate the proposed system or methods with potential for significant impact on preclinical, single, or multisite clinical studies. Partnerships must include at least one lead academic and one lead industrial organization large or small among their numbers. For either preclinical or clinical research, funding may be requested for limited additional copies of prototype systems and methods in order to optimize and validate them across different platforms and/or research sites. Each partnership is encouraged to plan to solve its choice of targeted cancer problem within the five year funding period. This FOA supports clinical trials that emphasize optimization and validation of the performance of imaging systems, including devices, agents and/or methods. It will not support commercial production.
Note that this revised PAR has provided: (a) a revised definition of translational research consistent with the NCI Translational Research Working Group (TRWG) recommendations, (b) a definition of innovation within the context of the TRWG recommendation, (c) examples of translational research for current commercial and next generation of imaging platforms and (d) modified review criteria within the context of the TRWG recommendations. The intent of the revised PAR is to encourage applications with a strong translational research focus. Note that investigators interested in the creation of research resources to assist in validation of imaging technologies are encouraged to explore collaboration with research networks (U01, U54) consistent with the PAR goals.
See NIH Guide Announcement http://grants.nih.gov/grants/guide/pa-files/PAR-10-169.html